What will be interesting is, as I mentioned some time ago, will they be 'dosing/looking' for evidence in these trials that its actually working?? Could they be looking to confirm it works well enough in the early trials to go for expedited approval, no need to run a full PH 3 for example. Wonder if someone will ask this during one of their 'conference' or 'trial update' calls..
NERVGEN PHARMA ANNOUNCES COMPLETION OF DOSING OF ALL SUBJECTS IN
PHASE 1 CLINICAL TRIAL OF PROPRIETARY DRUG CANDIDATE NVG-291
- Completed NVG-291 dosing of subjects in Phase 1 clinical trial
- Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023
- NVG-291 has been demonstrated in preclinical studies to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination and plasticity
Vancouver, Canada. February 14, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial of the Company's proprietary lead compound, NVG-291, have completed dosing. The Company now plans to initiate a Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury in Q3 2023. Based on the encouraging results from preclinical studies, the Company plans to evaluate the efficacy of NVG-291 versus placebo in two cohorts: individuals with a chronic injury (1-10 years post-injury) and individuals with a subacute injury (10-49 days post-injury). In preclinical studies of spinal cord injury, NervGen’s NVG-291 has been demonstrated to promote neural repair mechanisms, including axonal regeneration, remyelination and plasticity.
Read more …